BML, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,882 JPY | -0.89% |
|
-2.14% | -3.90% |
| Sales 2024 * | 138B 886M | Sales 2025 * | 141B 906M | Capitalization | 113B 729M |
|---|---|---|---|---|---|
| Net income 2024 * | 6.37B 40.93M | Net income 2025 * | 6.67B 42.86M | EV / Sales 2024 * | 0.26 x |
| Net cash position 2024 * | 78.11B 502M | Net cash position 2025 * | 72.37B 465M | EV / Sales 2025 * | 0.29 x |
| P/E ratio 2024 * |
17.7
x | P/E ratio 2025 * |
16.8
x | Employees | 4,415 |
| Yield 2024 * |
2.75% | Yield 2025 * |
2.87% | Free-Float | 56.19% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.86% | ||
| 1 week | -2.14% | ||
| Current month | -0.89% | ||
| 1 month | -4.06% | ||
| 3 months | +1.16% | ||
| 6 months | +2.82% | ||
| Current year | -3.90% |
1 week
2 873.00
2 966.00
1 month
2 873.003 125.00
Current year
2 613.003 125.00
1 year
2 594.003 250.00
3 years
2 594.004 985.00
5 years
2 307.004 985.00
10 years
1 360.504 985.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kensuke Kondo
PSD | President | 57 | 94-05-31 |
Yuji Yamashita
CTO | Chief Tech/Sci/R&D Officer | 58 | 88-10-31 |
Nobuki Arai
ADM | Chief Administrative Officer | 64 | 05-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kensuke Kondo
PSD | President | 57 | 94-05-31 |
Nobuki Arai
ADM | Chief Administrative Officer | 64 | 05-05-31 |
Tatsuharu Arai
BRD | Director/Board Member | 67 | 21-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 23 M€ | +1.71% | - | |
| 0.10% | 19 M€ | +3.17% | ||
| 0.02% | 73 M€ | +11.61% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2,882 | -0.89% | 18 800 |
| 24-04-24 | 2,908 | -0.14% | 38,100 |
| 24-04-23 | 2,912 | -1.42% | 40,200 |
| 24-04-22 | 2,954 | +1.79% | 42,200 |
| 24-04-19 | 2,902 | -1.49% | 67,900 |
Delayed Quote Japan Exchange, April 25, 2024 at 12:50 am EDT
More quotes
BML, INC. is mainly engaged in the clinical testing as well as related business. The Testing segment engages in the commissioned work of clinical testing. The Medical Information Systems segment is engaged in the manufacturing and sales of system equipment for medical institutions, as well as provision of medical information service.
Calendar
2024-05-09
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
2,908
JPY
Average target price
3,033
JPY
Spread / Average Target
+4.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.90% | 731M | |
| -16.65% | 8.34B | |
| +39.98% | 3.59B | |
| -32.00% | 2.75B | |
| -7.71% | 2.48B | |
| -10.00% | 2.32B | |
| -13.29% | 1.79B | |
| -19.46% | 1.54B | |
| -40.57% | 1.21B | |
| +9.70% | 1.13B |
- Stock Market
- Equities
- 4694 Stock
